REG - GSK PLC - Directorate Change

GSKAnnouncement

21/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250221:nRSU9367Xa&default-theme=true

RNS Number : 9367X  GSK PLC  21 February 2025

Issued: 21 February 2025, London UK

 

GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director

 

Dr Jesse Goodman to retire after 9 years of service

 

 

GSK plc (LSE/NYSE: GSK) has today announced that Dr Gavin Screaton will join
the Board of the Company as a Non-Executive Director from 1 May 2025. Dr
Screaton's appointment follows a search to replace the skills and experience
of Dr Jesse Goodman who steps down from the Board after the company's Annual
General Meeting in May 2025, after nine years of service.

 

Dr Screaton is currently Head of the world-leading(1) Medical Sciences
Division at the University of Oxford, and an expert in the field of immunology
and infectious diseases, two areas of science critical to GSK.

 

Dr Screaton is a Fellow of the Academy of Medical Sciences, a Fellow of the
Royal College of Physicians, and a former Senior Investigator at the National
Institute for Health Research in the United Kingdom. He is also a
Non-Executive Director of Oxford University Hospitals NHS Foundation Trust and
a Trustee of the Jenner Vaccine Foundation. He also co-founded RQ Bio, a
biotech company focused on development of preventative medicines to provide
immunity and protection against viral infectious diseases.

 

On appointment, Dr Screaton will become a member of the GSK Board Science
Committee and the Corporate Responsibility Committee.

 

Sir Jonathan Symonds, Chair of GSK said, "We are delighted to welcome Gavin to
the Board of GSK. His deep expertise in immunology and infectious diseases,
which are core areas of scientific research focus for GSK, together with his
considerable experience in public health, will bring valuable perspective to
the Board.

 

The appointment will also help to replace the skillset and experience of Jesse
Goodman who steps down from the GSK Board after nine years of service. As a
former FDA Chief Scientist, the Board as a whole and the Science Committee in
particular, has benefitted hugely from Jesse's wealth of expertise in
infectious diseases, regulation and public health. He has made a fantastic
contribution to GSK and we wish Jesse all the very best for the future."

 

 

 

 

 

_________________________

(1)The University of Oxford is ranked first in Times Higher Education (THE)
World University Rankings for Medicine, as of January 2025. This is the 14th
consecutive year that Oxford has led the THE subject rankings in medicine.

 

Notes:

 

   1.   The appointment of Dr Screaton was made by the Board on the
   recommendation of the Nominations & Corporate Governance Committee. The
   Committee conducted an extensive search and selection process for this
   appointment, using an external search firm, which is a signatory of the
   Voluntary Code of Conduct for Executive Search Firms. The external search firm
   provided a comprehensive list of candidates who were approached, evaluated and
   interviewed against an agreed set of criteria aligned to the Board's target
   skills matrix. The Board satisfied itself that Dr Screaton had the experience
   and time available to carry out the role.

   2.   The Board has determined that Dr Screaton is an independent
   Non-Executive Director in accordance with the UK Corporate Governance Code.

   3.   Dr Screaton will receive the standard basic fee for a Non-Executive
   Director of £122,258 per annum (including travel allowance). He will also
   receive fees of £30,000 per annum as a scientific and medical expert. Dr
   Screaton will be required to build towards a share ownership requirement of
   GSK shares in accordance with the Company's shareholder approved Non-Executive
   remuneration policy.

   4.   "Scientific and Medical Expert" - The Board designates Non-Executive
   Directors whose expertise or backgrounds as renowned medical scientists,
   researchers, or physicians mean that they can bring scientific or industry
   expertise to the Board's deliberations.

   5.   Dr Screaton does not have a service contract. He has a letter of
   appointment which may be viewed by contacting the Company Secretary at the
   Company's registered office.

   6.   There are no further disclosures to be made in respect of Dr Screaton's
   appointment under Listing Rule 6.4.8R

   7.   As of 1 May 2025, the Board of GSK will comprise:

Sir Jonathan Symonds      Non-Executive Chair
   Emma Walmsley             Chief Executive Officer
   Julie Brown               Chief Financial Officer
   Charles Bancroft          Senior Independent Non-Executive Director
   Elizabeth McKee Anderson  Independent Non-Executive Director
   Dr Hal Barron             Non-Executive Director
   Dr Anne Beal              Independent Non-Executive Director
   Wendy Becker              Independent Non-Executive Director
   Dr Hal Dietz              Independent Non-Executive Director
   Dr Jesse Goodman          Independent Non-Executive Director
   Dr Jeannie Lee            Independent Non-Executive Director
   Dr Gavin Screaton         Independent Non-Executive Director
   Dr Vishal Sikka           Independent Non-Executive Director

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley                  +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn             +1 202 603 5003       (Washington DC)

 Investor Relations:  Annabel Brownrigg-Gleeson  +44 (0) 7901 101944   (London)
                      James Dodwell              +44 (0) 20 8047 2406  (London)
                      Mick Readey                +44 (0) 7990 339653   (London)
                      Camilla Campbell           +44 (0) 7803 050238   (London)
                      Steph Mountifield          +44 (0) 7796 707505   (London)
                      Jeff McLaughlin            +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco           +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q4 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADBLFLELLZBBX